A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant clostridium difficile infection in mice

Journal of Infectious Diseases

Volumn 210, Issue 6, 2014, Pages 964-972

  Yang, Zhiyong ^a   Schmidt, Diane ^e   Liu, Weilong ^e,g   Li, Shan ^a,h   Shi, Lianfa ^a   Sheng, Jinliang ^a,i   Chen, Kevin ^a   Yu, Hua ^a   Tremblay, Jacqueline M ^e   Chen, Xinhua ^f   Piepenbrink, Kurt H ^b   Sundberg, Eric J ^b,c,d   Kelly, Ciaran P ^f   Bai, Guang ^a   Shoemaker, Charles B ^e   Feng, Hanping ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

^c Department of Medicine ^*  (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e TUFTS UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Electronic Journal of Emerging Infectious Diseases   (China)

^h SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

ⁱ SHIHEZI UNIVERSITY   (China)

Author keywords

Antibody; Clostridium difficile; Immunotherapy; Toxins; VHH

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY ABA; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEMALE; HEAVY CHAIN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VH HEAVY CHAIN ONLY;

ANTIBODY; CLOSTRIDIUM DIFFICILE; IMMUNOTHERAPY; TOXINS; VHH;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BINDING SITES, ANTIBODY; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; NEUTRALIZATION TESTS;

EID: 84907102875     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu196     Document Type: Article

References (50)

1. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007; 23:4-9.
2. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008; 359:1932-40.
3. Siemann M, Koch-Dorfler M, Rabenhorst G. Clostridium difficileassociated diseases. The clinical courses of 18 fatal cases. Intensive Care Med 2000; 26:416-21.
4. Huang H, Fang H, Weintraub A, Nord CE. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 2009; 15:1170-3.
5. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
6. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-10.
7. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
8. Butler MM, Shinabarger DL, Citron DM, et al. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 2012; 56:4786-92.
9. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:994-1002.
10. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-87.
11. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012; 30:4249-58.
12. Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80:2678-88.
13. Kelly CP, Pothoulakis C, Vavva F, et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996; 40:373-9.
14. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
15. Roberts A, McGlashan J, Al-Abdulla I, et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun 2012; 80:875-82.
16. Marozsan AJ, Ma D, Nagashima KA, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis 2012; 206:706-13.
17. Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009; 198:157-74.
18. Adams H, Brummelhuis W, Maassen B, et al. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol Bioeng 2009; 104:143-51.
19. Tremblay JM, Mukherjee J, Leysath CE, et al. A single VHH-based toxin neutralizing agent and an effector antibody protects mice against challenge with Shiga toxins 1 and 2. Infect Immun 2013; 81:4592-603.
20. Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies. Methods Mol Biol 2012; 911:211-39.
21. Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 2011; 286:8961-76.
22. Yang G, Zhou B, Wang J, et al. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 2008; 8:192.
23. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods 2007; 324:13-25.
24. Tremblay JM, Kuo CL, Abeijon C, et al. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 2010; 56:990-8.
25. Mukherjee J, Tremblay JM, Leysath CE, et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 2012; 7:e29941.
26. Vance DJ TJ, Mantis NJ, Shoemaker CB. Stepwise Engineering of Heterodimeric Single Domain Camelid VHH Antibodies that Passively Protect Mice from Ricin Toxin. J Biol Chem 2013; 288:36538-47.
27. Stabler RA, Dawson LF, Valiente E, et al. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One 2012; 7:e31559.
28. He M, Sebaihia M, Lawley TD, et al. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci U S A 2010; 107:7527-32.
29. He X, Sun X, Wang J, et al. Antibody-enhanced, Fc gamma receptormediated endocytosis of Clostridium difficile toxin A. Infect Immun 2009; 77:2294-303.
30. Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80:2678-88.
31. Castagliuolo I, Sardina M, Brun P, et al. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun 2004; 72:2827-36.
32. Olling A, Goy S, Hoffmann F, Tatge H, Just I, Gerhard R. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One 2011; 6: e17623.
33. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006; 74:6339-47.
34. Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of clostridium difficile toxin A with single-domain antibodies targeting the cell-receptor binding domain. J Biol Chem 2011; 286:8961-76.
35. Permpoonpattana P, Hong HA, Phetcharaburanin J, et al. Immunisation with Bacillus spores expressing toxin A peptide repeats protects against infection with toxin A+ B+ strains of Clostridium difficile. Infect Immun 2011; 79:2295-302.
36. Leuzzi R, Spencer J, Buckley A, et al. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun 2013; 81:2851-60.
37. Lanis JM, Barua S, Ballard JD. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 2010; 6:e1001061.
38. Stabler RA, He M, Dawson L, et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10: R102.
39. Sambol SP, Merrigan MM, Lyerly D, Gerding DN, Johnson S. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun 2000; 68:5480-7.
40. Kim J, Pai H, Seo MR, Kang JO. Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections. BMC Infect Dis 2012; 12:109.
41. Huelsenbeck J, Dreger S, Gerhard R, Barth H, Just I, Genth H. Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. Infect Immun 2007; 75:801-9.
42. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7:526-36.
43. Steele J, Feng H, Parry N, Tzipori S. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis 2010; 201:428-34.
44. He X,Wang J, Steele J, et al. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods 2009b; 78:97-100.
45. Steele J, Chen K, Sun X, et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 2012; 205:384-91.
46. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009; 284:3273-84.
47. Tijink BM, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7:2288-97.
48. Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006; 54:1856-66.
49. Harmsen MM, Van Solt CB, Fijten HP, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 2005; 23:4926-34.
50. Harmsen MM, van Solt CB, Fijten HP, et al. Passive immunization of guinea pigs with llama single-domain antibody fragments against footand-mouth disease. Vet Microbiol 2007; 120:193-206.